Dr. Duplantier is a medicinal chemist with 20 years of industry, eight years of government, and three years of consulting experience in drug discovery and development. He has worked in all stages of early drug development, including hit-to-lead, lead optimization, candidate selection, and IND submission.
At LBG, he has helped clients successfully write and submit proposals for government funding, performed due diligence on potential in/out-licensed products, advised on medicinal chemistry, in vitro ADME, and in vivo PK strategies, and assisted with CMC development. He is also a Principal Investigator on an MCDC- awarded antiviral project.
Dr. Duplantier was a Laboratory Supervisor and Design Lead at Pfizer in the therapeutic areas of neuroscience, inflammation, allergy, and respiratory diseases and held leadership roles on a variety of multidisciplinary project teams. These efforts led to the delivery of four clinical drug candidates, allowing him the opportunity to be a member of several clinical candidate development teams.
In addition, Dr. Duplantier spent two years as a Senior Advisor at DTRA, where he managed the discovery and development of medical countermeasures (MCMs) to chemical weapons, was personally responsible for a $32 million per year portfolio of projects, and led a team to stand up an ADME Center for the DoD.
Dr. Duplantier served as a contractor at USAMRIID, where he was either Principal Investigator (PI) or co-investigator on multiple projects over six years and held leadership roles in the identification and optimization of therapeutics for the treatment of viral and bacterial infections and toxin poisoning. He was a key contributor to USAMRIID’s 2020 COVID-19 and 2014 EBOV outbreak responses to rapidly assess, evaluate, and prioritize externally partnered therapeutics and was part of a collaborative team between USAMRIID and Gilead that identified remdesivir as a potential treatment for EBOV infection.
In addition, he is an adjunct lecturer for Johns Hopkins University’s Advanced Academic Programs and has published more than 60 research articles, book chapters, and patent applications.
Dr. Duplantier received a Ph.D. in Organic Chemistry from the Massachusetts Institute of Technology and a B.S. in Chemistry from the University of New Orleans.
